Approaches to Treating Philadelphia-negative Acute Lymphoblastic Leukemia

This chapter discusses the treatment and outcomes of patients with Philadelphia-negative Acute Lymphoblastic Leukemia (ALL), highlighting the challenges of managing the disease historically and the improved tools and therapies available today. It covers the use of immune therapy, particularly PKI, and the potential use of Punatopin, a TKI inhibitor, in the treatment of pH positive ALL. The chapter also addresses the question of avoiding chemotherapy through the use of punatinate and blinga, and the impact of age on treatment outcomes.